223 related articles for article (PubMed ID: 32394749)
1. Cabozantinib as a second-line treatment option in hepatocellular carcinoma.
D'Angelo A; Sobhani N; Bagby S; Casadei-Gardini A; Roviello G
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):623-629. PubMed ID: 32394749
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib for the treatment of hepatocellular carcinoma.
Personeni N; Rimassa L; Pressiani T; Smiroldo V; Santoro A
Expert Rev Anticancer Ther; 2019 Oct; 19(10):847-855. PubMed ID: 31603008
[No Abstract] [Full Text] [Related]
3. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
Shang R; Song X; Wang P; Zhou Y; Lu X; Wang J; Xu M; Chen X; Utpatel K; Che L; Liang B; Cigliano A; Evert M; Calvisi DF; Chen X
Gut; 2021 Sep; 70(9):1746-1757. PubMed ID: 33144318
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor.
Markowitz JN; Fancher KM
Pharmacotherapy; 2018 Mar; 38(3):357-369. PubMed ID: 29283440
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma.
Deeks ED
Target Oncol; 2019 Feb; 14(1):107-113. PubMed ID: 30767164
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
[TBL] [Abstract][Full Text] [Related]
10. Novel Pyridine Bioisostere of Cabozantinib as a Potent
Karmacharya U; Guragain D; Chaudhary P; Jee JG; Kim JA; Jeong BS
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575841
[TBL] [Abstract][Full Text] [Related]
11. CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.
Wang DD; Chen Y; Chen ZB; Yan FJ; Dai XY; Ying MD; Cao J; Ma J; Luo PH; Han YX; Peng Y; Sun YH; Zhang H; He QJ; Yang B; Zhu H
Mol Cancer Ther; 2016 Dec; 15(12):2916-2925. PubMed ID: 27638856
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
Kelley RK; W Oliver J; Hazra S; Benzaghou F; Yau T; Cheng AL; Rimassa L
Future Oncol; 2020 Jul; 16(21):1525-1536. PubMed ID: 32491932
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence.
Santoni M; Iacovelli R; Colonna V; Klinz S; Mauri G; Nuti M
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1029-1054. PubMed ID: 34445927
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials.
Cammarota A; Zanuso V; D'Alessio A; Pressiani T; Personeni N; Rimassa L
Expert Opin Investig Drugs; 2022 Apr; 31(4):401-413. PubMed ID: 35072565
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
16. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.
Kelley RK; Meyer T; Rimassa L; Merle P; Park JW; Yau T; Chan SL; Blanc JF; Tam VC; Tran A; Dadduzio V; Markby DW; Kaldate R; Cheng AL; El-Khoueiry AB; Abou-Alfa GK
Clin Cancer Res; 2020 Sep; 26(18):4795-4804. PubMed ID: 32636319
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
Personeni N; Pressiani T; Rimassa L
Future Oncol; 2019 Jul; 15(21):2449-2462. PubMed ID: 31204849
[TBL] [Abstract][Full Text] [Related]
18. Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue.
Di Nunno V; Frega G; Gatto L; Brandi G; Massari F
Future Oncol; 2019 Feb; 15(6):563-565. PubMed ID: 30648889
[No Abstract] [Full Text] [Related]
19. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives.
Trojan J
Drugs; 2020 Aug; 80(12):1203-1210. PubMed ID: 32671719
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
